SEER
Seer, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.94
−2.51%Year over year
Reported trailing growth
- Revenue
- -13.3%
- EBITDA
- +22.4%
- EBIT
- +20.5%
- EPS
- +10.9%
- Free cash flow
- +18.9%
- Operating cash flow
- +16.0%
Forward estimates
Based on analyst estimates
- Revenue
- +42.3%
- EBITDA
- +20.4%
- EPS
- +16.0%
Three-year CAGR
- Revenue
- +3.2%
- EBITDA
- +10.5%
- EBIT
- +22.1%
- Net income
- +15.0%
- EPS
- +7.9%
- Free cash flow
- +6.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026